View Cart (0 items)

Pharmaceutical

Another Ranbaxy facility lands on FDA blacklist

The U.S. Food and Drug Administration (FDA) has added Ranbaxy's Toansa plant to the list of Indian facilities included on the consent decree dated January 2012.
Read More

Israel's Teva to buy NuPathe for $144 million

Pennsylvania-based NuPathe specializes in therapeutics for diseases of the central nervous system (CNS), including neurological and psychiatric disorders.
Read More

US, European watchdogs join forces to regulate generic drugs

The European Medicines Agency and the U.S. Food and Drug Administration have started a joint program for sharing information on bioequivalence studies required during the process of approval for generic drugs.
Read More

Global spending on medicines to grow by up to 6% per year through 2017

The key factors that will drive global drug markets are better access to medicines due to rising disposable income in developing countries and more favorable economic conditions in emerging markets.
Read More

FDA imposes new ban on Wockhardt drugs

Indian generic drug maker Wockhardt has been hit by a U.S. import alert for the second time this year.
Read More

Chinese anti-trust authorities launch probe into Bayer

German pharmaceutical giant Bayer AG is being investigated by Chinese authorities for unfair competition, becoming the latest foreign drug maker to come under examination in the Asian country.
Read More

Fatburner Dexaprine banned in UK, Netherlands

Slimming agent Dexaprine, produced by California-based company iForce Nutrition, has been banned in the Netherlands and the United Kingdom over concerns that the fatburner causes a number of life-threatening conditions.
Read More

Novartis feels the heat as China opens another bribery probe

Chinese authorities are stepping up their crusade against widespread bribery in the pharmaceutical sector with a newly launched investigation.
Read More

Chinese pharma probe spreads to two Danish drug makers

Western pharmaceutical companies are coming under increased scrutiny in China following the bribery accusations leveled last month against GlaxoSmithKline (GSK).
Read More

European biotechs back on venture capital radar

Venture capital firms are once again warming to European biotechnology players, which attracted a significant portion of the venture capital invested globally in this sector during the second quarter.
Read More